Remove Drug Pricing Remove Labelling Remove Specialty Pharmacies
article thumbnail

Leveraging Partnerships With Drug Manufacturers To Overcome 340B Restrictions On Specialty Drugs

Proxsys Rx

At the same time, it’s no secret that, since the advent of 340B ESP in 2020, the drug manufacturers have imposed a raft of restrictions on 340B program savings that exist far outside the letter of the law as written by Congress in 1992. Every specialty pharmacy patient you serve should be monitored by a clinic pharmacist.

article thumbnail

Leveraging Partnerships With Drug Manufacturers To Overcome 340B Restrictions On Specialty Drugs

Proxsys Rx

At the same time, it’s no secret that, since the advent of 340B ESP in 2020, the drug manufacturers have imposed a raft of restrictions on 340B program savings that exist far outside the letter of the law as written by Congress in 1992. Every specialty pharmacy patient you serve should be monitored by a clinic pharmacist.

article thumbnail

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Putting Patients First Blog

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). It is crucial to consider how off-label uses will be evaluated and incorporated into the negotiation process.